Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Seeking Alpha
Company Participants Marino Garcia - President, CEO & Director Ryan Savitz - Chief Financial Officer & Chief Business Officer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Delma Caiati Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division [Audio Gap] Biotech Summit 2026. My name is Yatin Suneja. I'm joined here with my colleague, Delma Caiati. We will be moderating the next discussion with Dianthus Therapeutics. From the company, we have two executives here. We have Marino Garcia, the Chief Executive Officer. We also have Ryan Savitz, who is the Chief Financial Officer and also leading the charge on the business development front. Marino, always good to have you. Thank you for your time. Why don't you make some opening comments, then Delma and I will moderate the discussion with you. Marino Garcia President, CEO & Director Sure. So thank you to Guggenheim, and you specifically, for hosting us here
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $46.00 to $55.00. They now have an "outperform" rating on the stock.MarketBeat
- Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswire
- Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Jefferies Financial Group Inc. from $66.00 to $81.00. They now have a "buy" rating on the stock.MarketBeat
- Assessing Dianthus Therapeutics (DNTH) Valuation As Price To Book Sits Near 3x And Shares Show Mixed Returns [Yahoo! Finance]Yahoo! Finance
DNTH
Earnings
- 11/5/25 - Miss
DNTH
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/4/26 - Form 4
- DNTH's page on the SEC website